Qualigen Therapeutics (QLGN) Stock Price, News & Analysis

Company Overview

Qualigen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company’s research programs are centered on small-molecule and other targeted therapeutic approaches intended to address biological mechanisms associated with tumor growth and disease progression.

Qualigen’s development pipeline has included QN-302, an investigational small-molecule therapy being studied for potential use in oncology, including pancreatic cancer. The company has also pursued additional preclinical and clinical programs aimed at treating cancers and rare diseases. These products remain investigational and require further clinical development and regulatory review before they can be commercialized.

The company is based in the United States and has roots in the diagnostics industry through its predecessor and affiliated operations. Qualigen Therapeutics became the successor to Ritter Pharmaceuticals following a 2020 corporate transaction involving Qualigen, Inc. Its current business is primarily focused on advancing its therapeutic pipeline rather than providing established commercial medical products.

Key Stats

• Today's Range: $1.42 to $1.70
• 50-Day Range: $0.65 to $1.55
• 52-Week Range: $1.61 to $8.81
• Volume: 990,956 shs
• Average Volume: 1.52 million shs
• Market Capitalization: $2.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Qualigen Therapeutics Stock Analysis - MarketRank™

Qualigen Therapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Qualigen Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Qualigen Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Qualigen Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Qualigen Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for QLGN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Qualigen Therapeutics does not currently pay a dividend.

Dividend Growth

Qualigen Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Qualigen Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.80% of the stock of Qualigen Therapeutics is held by insiders.

Percentage Held by Institutions

3.18% of the stock of Qualigen Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 11/14/2025
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: Software
• Sub-Industry: Application Software
• Current Symbol: NASDAQ:QLGN
• CIK: 1460702
• Web: www.qualigeninc.com
• Phone: (760) 918-9165
• Fax: N/A
• Employees: 50
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): ($7.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -202.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.71
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.12) per share
• Price / Book: -0.40

Miscellaneous

• Outstanding Shares: 1,695,000
• Free Float: 1,664,000
• Market Cap: $2.81 million
• Optionable: Not Optionable
• Beta: 0.24